US Democrats spearheaded by Henry Waxman intend to re-table a
stalled piece of legislation that would allow US Food and Drug
Administration (FDA) approval of generic biodrugs, which they claim
would result in cost savings for patients...
US-based firm Xcellerex yesterday announced it has completed the
second half of a $20m (€15.4m) financing deal, raising $11m to
speed up commercialisation of its innovative disposable
manufacturing technology for vaccines and biotherapeutics.
India's Dishman Pharmaceuticals & Chemicals is planning to snap
up biotech and nanotech contract research organisation (CRO)
companies in Europe and in the US within drug conjugates to expand
their biologics capability.
The Biotechnology Industry Organization (BIO) urged the World
Health Organization (WHO) to change its International
Nonproprietary Names (INN) policy for biological products at a
meeting last week in Geneva.
The European Commission continues to be accused by European
industry of pushing 'green policies' that are stifling progress and
global competitiveness - the controversial REACH chemicals
legislation remains a sore point.
MedImmune has embarked on an expansion of its biologics
manufacturing facility in Frederick, Maryland, to ramp up its cell
culture production capacity, as several of its monoclonal
antibodies (MAbs) approach commercialisation.
Nabi Biopharmaceuticals has obtained the exclusive rights to use a
plasma protein purification technology from ProMetic Life Sciences
in the large-scale development and manufacture of its hyperimmune
products, cutting production costs...
Seattle drug firm ZymoGenetics has taken Bristol-Myers Squibb (BMS)
to court for infringement of its fusion protein technology patents
by several products, including arthritis medication Orencia